Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine

Simple item page
dc.contributor.authorSpearman, C W N
dc.contributor.authorSonderup, Mark W
dc.date.accessioned2021-10-08T07:20:28Z
dc.date.available2021-10-08T07:20:28Z
dc.date.issued2014
dc.description.abstractHepatitis B is a global public health issue, with some 2 billion people having current or past infection. In Africa, 65 million are chronically infected, an estimated 2.5 million of them in South Africa (SA). Hepatitis B and the associated complications of cirrhosis and hepatocellular carcinoma are entirely vaccine preventable. SA was one of the first ten countries in Africa to introduce universal hepatitis B vaccination in April 1995, but has no birth dose or catch-up programme. Although universal infant vaccination in SA has been successful in increasing population immunity to hepatitis B, improvements in terms of implementing protocols to screen all pregnant mothers for hepatitis B surface antigen (HBsAg) and ensuring full hepatitis B coverage, especially in rural areas, is justified. The World Health Organization has recommended a birth dose of hepatitis B vaccine in addition to the existing hepatitis B vaccine schedule in order to further decrease the risk of perinatal transmission. We recommend that SA implement a birth-dose vaccine into the existing schedule to attenuate the risk of perinatal transmission, prevent breakthrough infections and decrease HBsAg carriage in babies born to HIV-positive mothers.
dc.identifier.apacitationSpearman, C. W. N., & Sonderup, M. W. (2014). Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine. <i>South African Medical Journal</i>, 104(9), 610 - 177. http://hdl.handle.net/11427/34928en_ZA
dc.identifier.chicagocitationSpearman, C W N, and Mark W Sonderup "Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine." <i>South African Medical Journal</i> 104, 9. (2014): 610 - 177. http://hdl.handle.net/11427/34928en_ZA
dc.identifier.citationSpearman, C.W.N. & Sonderup, M.W. 2014. Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine. <i>South African Medical Journal.</i> 104(9):610 - 177. http://hdl.handle.net/11427/34928en_ZA
dc.identifier.issn0038-2469
dc.identifier.ris TY - Journal Article AU - Spearman, C W N AU - Sonderup, Mark W AB - Hepatitis B is a global public health issue, with some 2 billion people having current or past infection. In Africa, 65 million are chronically infected, an estimated 2.5 million of them in South Africa (SA). Hepatitis B and the associated complications of cirrhosis and hepatocellular carcinoma are entirely vaccine preventable. SA was one of the first ten countries in Africa to introduce universal hepatitis B vaccination in April 1995, but has no birth dose or catch-up programme. Although universal infant vaccination in SA has been successful in increasing population immunity to hepatitis B, improvements in terms of implementing protocols to screen all pregnant mothers for hepatitis B surface antigen (HBsAg) and ensuring full hepatitis B coverage, especially in rural areas, is justified. The World Health Organization has recommended a birth dose of hepatitis B vaccine in addition to the existing hepatitis B vaccine schedule in order to further decrease the risk of perinatal transmission. We recommend that SA implement a birth-dose vaccine into the existing schedule to attenuate the risk of perinatal transmission, prevent breakthrough infections and decrease HBsAg carriage in babies born to HIV-positive mothers. DA - 2014 DB - OpenUCT DP - University of Cape Town IS - 9 J1 - South African Medical Journal LK - https://open.uct.ac.za PY - 2014 SM - 0038-2469 T1 - Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine TI - Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine UR - http://hdl.handle.net/11427/34928 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/34928
dc.identifier.vancouvercitationSpearman CWN, Sonderup MW. Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine. South African Medical Journal. 2014;104(9):610 - 177. http://hdl.handle.net/11427/34928.en_ZA
dc.language.isoeng
dc.publisher.departmentDivision of Hepatology
dc.publisher.facultyFaculty of Health Sciences
dc.sourceSouth African Medical Journal
dc.source.journalissue9
dc.source.journalvolume104
dc.source.pagination610 - 177
dc.source.urihttps://dx.doi.org/10.7196/SAMJ.8607
dc.subject.otherHepatitis B
dc.subject.otherVaccine
dc.subject.otherHepatocellular carcinoma
dc.titlePreventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine
dc.typeJournal Article
uct.type.publicationResearch
uct.type.resourceJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
SpearmanCWN_Preventing_hepa_2014.pdf
Size:
86.85 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles